Literature DB >> 25558186

Analysis of Partially Incomplete Tables of Breast Cancer Characteristics with an Ordinal Variable.

B Nebiyou Bekele1, Luis E Nieto-Barajas2, Mark F Munsell3.   

Abstract

Our goal is to model the joint distribution of a series of 4×2×2×2 contingency tables for which some of the data are partially collapsed (i.e., aggregated in as few as two dimensions). More specifically, the joint distribution of 4 clinical characteristics in breast cancer patients is estimated. These characteristics include estrogen receptor status (positive/negative), nodal involvement (positive/negative), HER2-neu expression (positive/negative), and stage of disease (I, II, III, IV). The joint distribution of the first three characteristics is estimated conditional on stage of disease and we propose a dynamic model for the conditional probabilities that let them evolve as the stage of disease progresses. The dynamic model is based on a series of Dirichlet distributions whose parameters are related by a Markov prior structure (called dynamic Dirichlet prior). This model makes use of information across disease stage (known as "borrowing strength") and provides a way of estimating the distribution of patients with particular tumor characteristics. In addition, since some of the data sources are aggregated, a data augmentation technique is proposed to carry out a meta-analysis of the different datasets.

Entities:  

Keywords:  Bayesian methods; CISNET; Markov Dirich-let sequence; breast cancer; data augmentation; dynamic model; meta-analysis

Year:  2012        PMID: 25558186      PMCID: PMC4280505          DOI: 10.1080/15598608.2012.719805

Source DB:  PubMed          Journal:  J Stat Theory Pract        ISSN: 1559-8608


  8 in total

1.  A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.

Authors:  Michele De Laurentiis; Grazia Arpino; Erminia Massarelli; Angela Ruggiero; Chiara Carlomagno; Fortunato Ciardiello; Giampaolo Tortora; Diego D'Agostino; Francesca Caputo; Giuseppe Cancello; Emilia Montagna; Luca Malorni; Luigia Zinno; Rossella Lauria; Angelo Raffaele Bianco; Sabino De Placido
Journal:  Clin Cancer Res       Date:  2005-07-01       Impact factor: 12.531

2.  A comparison of methods for fixed effects meta-analysis of individual patient data with time to event outcomes.

Authors:  Catrin Tudur Smith; Paula Ruth Williamson
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

3.  Effect of screening and adjuvant therapy on mortality from breast cancer.

Authors:  Donald A Berry; Kathleen A Cronin; Sylvia K Plevritis; Dennis G Fryback; Lauren Clarke; Marvin Zelen; Jeanne S Mandelblatt; Andrei Y Yakovlev; J Dik F Habbema; Eric J Feuer
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

4.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells.

Authors:  R M Hudziak; J Schlessinger; A Ullrich
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Overexpression of the human EGF receptor confers an EGF-dependent transformed phenotype to NIH 3T3 cells.

Authors:  P P Di Fiore; J H Pierce; T P Fleming; R Hazan; A Ullrich; C R King; J Schlessinger; S A Aaronson
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

8.  A comparison of five immunohistochemical biomarkers and HER-2/neu gene amplification by fluorescence in situ hybridization in white and Korean patients with early-onset breast carcinoma.

Authors:  Doo Ho Choi; Dong Bok Shin; Min Hyuk Lee; Dong Wha Lee; Devika Dhandapani; Darryl Carter; Bonnie L King; Bruce G Haffty
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

  8 in total
  1 in total

1.  Which strategies reduce breast cancer mortality most? Collaborative modeling of optimal screening, treatment, and obesity prevention.

Authors:  Jeanne Mandelblatt; Nicolien van Ravesteyn; Clyde Schechter; Yaojen Chang; An-Tsun Huang; Aimee M Near; Harry de Koning; Ahmedin Jemal
Journal:  Cancer       Date:  2013-04-26       Impact factor: 6.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.